# Can Sermorelin enhance radiosensitivity in non-small cell lung cancer treatment?

Canonical source: https://retacompare.com/research/can-sermorelin-enhance-radiosensitivity-in-non-small-cell-lung-cancer-treatment

Peptide Longevity Q&A · 2025-04-01


    Sermorelin, through its action as a growth hormone-releasing hormone (GHRH) antagonist, has shown potential to enhance radiosensitivity in non-small cell lung cancer (NSCLC) cells. This effect was observed in preclinical studies where GHRH antagonists increased the efficacy of ionizing radiation.

What the research shows

The study investigated the effects of GHRH antagonists, specifically MIA-602 and MIA-690, on radiosensitivity in NSCLC cell lines, A549 and H522. The researchers exposed these cells to ionizing radiation (IR) and the GHRH antagonists, both individually and in combination. They measured cell viability and proliferation using various assays, including MTT, BrdU, flow cytometry, and clonogenic assays. Additionally, they analyzed gene and protein expression, signaling pathways, and markers of apoptosis through real-time PCR, Western blotting, annexin staining, and caspase-3 assays.

Why it matters for longevity

The findings suggest that GHRH antagonists like Sermorelin may play a role in cancer treatment by enhancing the effectiveness of radiotherapy. By increasing radiosensitivity, these compounds could potentially improve outcomes for patients with NSCLC, a common and aggressive form of lung cancer. This has implications not only for cancer therapy but also for understanding how hormonal regulation can influence cancer biology and longevity. The ability to modulate cellular responses to therapy may contribute to healthier aging by improving treatment efficacy and reducing the burden of cancer-related morbidity.

Key findings at a glance

GHRH antagonists MIA-602 and MIA-690 were studied in NSCLC cell lines.

Combination treatment of GHRH antagonists with ionizing radiation significantly reduced cell viability and proliferation.

GHRH antagonists decreased the expression of GHRH receptor and its oncogenic splice variant.

Apoptotic markers were upregulated, while antiapoptotic proteins like Bcl-2 were downregulated.

MIA-690 prevented radioresistance and reduced epithelial-mesenchymal transition.

Both MIA-602 and MIA-690 enhanced radiosensitivity in primary human NSCLC cells.

How Sermorelin works (background)

Sermorelin is a synthetic peptide that acts as a GHRH antagonist, stimulating the release of growth hormone from the pituitary gland. This mechanism is believed to influence various biological processes, including cell proliferation, apoptosis, and tumor growth. In the context of cancer, GHRH antagonists may alter the tumor microenvironment, enhance the effectiveness of radiation therapy, and modulate signaling pathways involved in cell survival and death. The research indicates that these peptides can affect the expression of key genes and proteins associated with cancer progression and treatment response.

Safety, caveats, and what we don't yet know

While the study presents promising findings regarding the potential of GHRH antagonists in enhancing radiosensitivity, it is important to note that this research is preclinical and conducted in vitro. The effects observed in cell lines may not fully translate to clinical settings. Further studies are required to explore the safety and efficacy of Sermorelin and similar compounds in human subjects, particularly in combination with radiation therapy. Additionally, the long-term effects and potential side effects of using GHRH antagonists in cancer treatment remain to be fully understood.

Bottom line

Research indicates that Sermorelin, as a GHRH antagonist, may enhance radiosensitivity in non-small cell lung cancer treatment, potentially improving therapeutic outcomes when combined with radiation therapy.

Related questions

Can Sermorelin improve recovery after cancer treatment?

Research suggests that growth hormone-releasing hormones may play a role in recovery processes, but specific studies on Sermorelin's effects post-cancer treatment are limited and require further investigation.

Does Sermorelin affect aging-related muscle loss?

Sermorelin's role in stimulating growth hormone release may help mitigate muscle loss associated with aging, but more research is needed to confirm its effectiveness in this context.

What are the potential side effects of Sermorelin?

While Sermorelin is generally considered safe, potential side effects can include injection site reactions and hormonal imbalances. Ongoing research is needed to better understand its long-term safety profile.

Source: PubMed · Int J Mol Sci · published 2025-04-01.

## Sources

- PubMed · Int J Mol Sci: https://pubmed.ncbi.nlm.nih.gov/40244089/